26 results
424B3
PYXS
Pyxis Oncology Inc
30 Jun 23
Prospectus supplement
4:05pm
or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other … or disrupt Apexigen’s operations, including Apexigen’s ability to conduct its analyses, deliver test results, process claims and appeals, provide customer
S-4/A
dzdg3a tj
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
915tnf7tp
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
425
1sswvshy rkkr3
24 May 23
Business combination disclosure
7:05am
425
5n2o0y42vt
24 May 23
Business combination disclosure
7:03am
8-K
EX-2.1
4w1k6 nksmu
24 May 23
Pyxis Oncology to Acquire Apexigen
6:59am
10-K
cpt2sfz vkxm3ynev
29 Mar 22
Annual report
7:36am
10-Q
fbw 05hne
15 Nov 21
Quarterly report
7:54am
424B4
407xn74 83vz87ix0r
8 Oct 21
Prospectus supplement with pricing info
5:00pm
S-1/A
EX-10.14
1paepgg
30 Sep 21
IPO registration (amended)
9:11pm